Cerenome (PSTV) Total Liabilities (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Total Liabilities of $8.0 million for Q1 2026, down 77.72% year-over-year from $35.7 million in Q1 2025, and down 35.48% quarter-over-quarter from $12.3 million in Q4 2025.
Cerenome (PSTV) Total Liabilities (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Total Liabilities for 17 consecutive years, with $8.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 77.72% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $8.0 million (down 77.72% YoY), while the FY2025 annual figure was $12.3 million, down 20.88% from the prior year.
- Total Liabilities declined to $8.0 million in Q1 2026 per PSTV's latest filing, from $12.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $35.7 million in Q1 2025 and bottomed at $7.3 million in Q2 2025.
- Historically, Total Liabilities has averaged $13.7 million across 5 years, with a median of $12.2 million in 2024.
- Annual changes were most pronounced in 2025 — Total Liabilities surged 241.34% — and 2026, when it tumbled 77.72%.
- Plus Therapeutics' Total Liabilities stood at $17.4 million in 2022, then declined by 26.9% to $12.7 million in 2023, then rose by 22.35% to $15.6 million in 2024, then retreated by 20.88% to $12.3 million in 2025, then slumped by 35.48% to $8.0 million in 2026.
- Business Quant data shows PSTV's Total Liabilities at $8.0 million in Q1 2026, $12.3 million in Q4 2025, and $13.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 8.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.96 Mn |
| Dec 31, 2025 | 12.33 Mn |
| Sep 30, 2025 | 13.62 Mn |
| Jun 30, 2025 | 7.32 Mn |
| Mar 31, 2025 | 35.70 Mn |
| Dec 31, 2024 | 15.58 Mn |
| Sep 30, 2024 | 12.15 Mn |
| Jun 30, 2024 | 18.84 Mn |
| Mar 31, 2024 | 10.46 Mn |
| Dec 31, 2023 | 12.74 Mn |
| Sep 30, 2023 | 10.66 Mn |
| Jun 30, 2023 | 11.54 Mn |
| Mar 31, 2023 | 12.96 Mn |
| Dec 31, 2022 | 17.42 Mn |
| Sep 30, 2022 | 11.70 Mn |
| Jun 30, 2022 | 11.59 Mn |
| Mar 31, 2022 | 9.87 Mn |
| Dec 31, 2021 | 11.15 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Jun 30, 2021 | 8.89 Mn |